Adimab, a US-based healthcare company that uses yeast (pictured) to grow antibodies, has raised $4m in its series E round.
News provider Xconomy, which first revealed the regulatory filing, said the latest round was double the valuation of the series D round in October last year. Xconomy said the round was at a pre-money valuation of $520m with backing from all its previous investors that had provided less than $30m in aggregate across the five rounds.
Google Ventures, the corporate venturing unit of Google that invests $100m per year, led the D round in Adimab, with venture capital firms Borealis Ventures, OrbiMed Advisors, Polaris Venture Partners, and SV Life Sciences reinvesting.
The regulatory filing also said Robert Birnbaum from law firm Foley Hoag was on its board, alongside William Maris, co-head of Google Ventures.